Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.

Current opinion in investigational drugs (London, England : 2000) - 1 Feb 2006

Boone Lawrence R

Abstract excerpt

This review discusses the desired attributes of a next-generation HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) and highlights the properties of compounds currently or recently in clinical development. TMC-125 is currently in phase III clinical trials and on track to become the first NNRTI suitable for use in NNRTI-experienced patients. TMC-278 is structurally related to TMC-125, but is more potent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azepines
Share to Drug Design
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Reverse Transcriptase

Share to Nitriles

Share to Pyridazines

Share to Reverse Transcriptase Inhibitors

Share to Rilpivirine

Source

Identifiers

PMID: 16499282

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.PMID 16499282Read ↗

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.Semantic proximity Read ↗

Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update.Semantic proximity Read ↗

New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infectionsSemantic proximity Read ↗

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.Semantic proximity Read ↗

Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase InhibitorsSemantic proximity Read ↗

Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.Semantic proximity Read ↗

TMC 125 possibly effective against NNRTI-resistant HIV.Semantic proximity Read ↗

Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles.Semantic proximity Read ↗

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009)Semantic proximity Read ↗

In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.Semantic proximity Read ↗

The Current Status of the NNRTI Family of Antiretrovirals Used Against HIV InfectionSemantic proximity Read ↗

Druggability modification strategies of the diarylpyrimidine‐type non‐nucleoside reverse transcriptase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.